Genocea Biosciences

Genocea Biosciences

A biopharmaceutical company developing T cell vaccines and immunotherapies

Genocea is a biopharmaceutical company headquartered in Cambridge, Massachusetts that was founded by Lux and spun-out from Harvard Medical School in 2006.

ATLAS Platform

Genocea has a proprietary technology platform, ATLAS, which mimics the human immune system. The system is used find targets for adoptive cell therapies like chimeric antigen receptor (CAR-Ts) where a patient’s T cells are engineered to attack certain tumor cells.

ATLAS uses human immune cells to identify relevant antigens from libraries of pathogen proteins. Hundreds of human T cells are tested with thousands of potential antigens. The platform is used to identify targets most likely to illicit an immune response.

Products

GEN-003, GEN-004, and GEN-009

Genocea’s pipeline includes clinical-stage T cell-enabled product candidates such as GEN-003 for genital herpes, GEN-004 for pneumococcus and earlier stage programs in chlamydia, malaria and cancer immunotherapy.Genocea has a cancer vaccine candidate, GEN-009, which is in a Phase1/2a clinical trial as of January 2019 with estimated completion in 2022.

Partners

Boston Children's Hospital

Genocea has been partnered with Richard Malley, MD, at Boston Children’s Hospital since 2008. Together they are working on a vaccine for pneumococcal infections such as pneumonia and meningitis.ATLAS was developed by Dr. Darren Higgins at Harvard University.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Genocea Biosciences Series C round
30,000,000
October 10, 2012
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Rob Paull

Founder

Further reading

Title
Author
Link
Type
Date

Dosing underway in Phase 1/2a study of Genocea's cancer vaccine candidate GEN-009; shares up 22%

SA Editor Douglas W. House

Web

Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009

Genocea Biosciences, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 19, 2020
BioSpace
Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea's proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.